TABLE 3.
Postoperative complications and adverse effects in patients.
| Parameter | 5-FU (n = 145) | Control (n = 74) | ||||||
|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | Ⅳ | Ⅰ | Ⅱ | Ⅲ | Ⅳ | |
| Peritoneal effusion | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Pelvic effusion | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Fever | 7 | 4 | 0 | 0 | 1 | 7 | 0 | 0 |
| Diarrhea | 1 | 4 | 0 | 0 | 0 | 0 | 1 | 0 |
| Nausea/Vomiting | 4 | 1 | 0 | 0 | 5 | 0 | 0 | 0 |
| Anastomotic leakage | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulmonary infection | 0 | 2 | 0 | 0 | 1 | 6 | 0 | 0 |
| Incisional infection | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 |
| Ileus | 1 | 0 | 1 | 0 | 0 | 3 | 0 | 0 |
| Postoperative hemorrhage | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 |
Complications and adverse events were classified according to the National Cancer Institute common terminology criteria for adverse events (version 4.0) (Supplementary Table S1).
5-FU, 5-fluorouracil.